Morgan Stanley named three reasons for its positive opinion on Irish pharma company Jazz Pharmaceuticals PLC JAZZ 1.26% in a Monday report. The Analyst Analyst David Risinger upgraded shares of Jazz Pharma from Equal-weight from Overweight and increased the price target from $167 to $183. SourceStochastics are getting overbought, so the upside is coming to an end. $JAZZ, Jazz Pharmaceuticals plc / D